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Low Plasma Leptin Levels Contribute to Diabetic
Hyperphagia in Rats
Dana K. Sindelar, Peter J. Havel, Randy J. Seeley, Charles W. Wilkinson, Stephen C. Woods, 
and Michael W. Schwartz
The adipocyte hormone leptin reduces food intake in
normal animals. During uncontrolled type 1 diabetes,
plasma leptin levels fall, whereas food intake in-
creases. To test the hypothesis that low leptin levels
contribute to diabetic hyperphagia, we investigated the
e ffect on food intake of replacement of leptin at basal
plasma concentrations for 7 days in Long-Evans rats
with uncontrolled diabetes induced by streptozotocin
(STZ). One group of STZ diabetic rats received saline
(STZ + Sal) (n = 11), while the other group (STZ +
Lep) (n = 15) received a subcutaneous infusion of
recombinant rat leptin (100 µg ? k g– 1 ? d a y– 1) via
osmotic minipumps. A nondiabetic control group (Con)
(n = 11) received saline only. In the STZ + Sal group,
plasma leptin levels decreased by 75% (P < 0.05) from
2.4 ± 0.5 on the day before STZ/citrate buffer vehicle
( Veh) injection (day 0) to 0.6 ± 0.2 ng/ml on day 7. In
contrast, plasma leptin levels on days 3–7 were compa-
rable to pretreatment values in both the STZ + Lep
group (day 0: 2.6 ± 0.4 vs. day 7: 2.5 ± 0.3 ng/ml, NS) and
the Con group (day 0: 3.8 ± 0.4 vs. day 7: 2.9 ± 
1.0 ng/ml, NS). In the STZ + Sal group, daily food intake
increased gradually to values 43% above basal by day 7
(day 0: 24 ± 2 to day 7: 33 ± 3 g, P < 0.05), whereas food
intake did not increase in either the STZ + Lep group
(day 0: 24 ± 1 vs. day 7: 21 ± 2 g, NS), or the Con group
(day 0: 23 ± 1 vs. day 7: 23 ± 2 g). Plasma glucose lev-
els exceeded nondiabetic control values (7.7 ± 
0.2 mmol/l) in both diabetic groups, but were lower in
the STZ + Lep group (17.2 ± 1.8 mmol/l) than in the STZ
+ Sal group (24.3 ± 1.1 mmol/l, P < 0.05). To determine
if sensitivity to leptin-induced anorexia was affected by
STZ treatment, a second experiment was performed in
which the effect of intracerebroventricular leptin injec-
tion (at doses of 0.35, 1.0, or 3.5 µg) on food intake was
measured 10 days after STZ or Veh treatment. Leptin
suppressed both 4- and 24-h food intake in the two
groups to an equal extent at every dose (by 15, 22, and
35%, respectively). These findings support the hypoth-
esis that the effect of uncontrolled diabetes to lower
leptin levels contributes to diabetic hyperphagia and
that this effect is not due to altered leptin sensitivity.
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The hypothesis that body fat stores are subject tohomeostatic regulation proposes that humoral sig-nals generated in proportion to adiposity act in thecentral nervous system (CNS) to reduce food
intake and body weight (1,2). Insulin, secreted from the pan-
creatic b-cells, and leptin (3), secreted from adipocytes, are
both implicated in this homeostatic control system. Both hor-
mones are secreted in proportion to body fat stores (4,5) and
recent energy intake (6–8), and receptors for both insulin and
leptin are concentrated in hypothalamic areas that control food
intake and energy expenditure (9,10). Moreover, administra-
tion of either hormone into the brain (11–14) causes sus-
tained reductions of food intake and body weight, whereas
both insulin deficiency (as occurs in uncontrolled diabetes)
and leptin deficiency (as seen in o b/o b mice [3]) are associated
with marked hyperphagia. Leptin secretion depends on
insulin stimulation of the adipocyte (15–21), an effect that
appears to be mediated in part via increased adipocyte glucose
uptake (22). Thus, during uncontrolled insulin-deficient dia-
betes induced by streptozotocin (STZ), a marked decrease in
plasma concentrations of both insulin and leptin occurs, and
this effect precedes the onset of hyperphagia characteristic of
the diabetic state (23). Moreover, 2 days of insulin treatment
of diabetic animals partially restored plasma leptin levels and
reduced diabetic hyperphagia by half (23).
To g e t h e r, these findings suggest that diabetic hyperphagia
may result not from weight loss, glycosuria, or other metabolic
derangements of the diabetic state, but from the direct
effects of decreased signaling within the brain by leptin,
insulin, or both hormones. To investigate the role of leptin defi-
ciency per se as a mediator of diabetic hyperphagia, we
sought to determine whether maintenance of normal plasma
leptin levels in animals with uncontrolled diabetes attenuates
the hyperphagic response. Leptin was infused subcuta-
neously at a dose designed to maintain basal circulating lep-
tin concentrations and thereby prevent the hypoleptinemic
state characteristic of insulin-deficient diabetes. We also
investigated whether differences in the sensitivity to leptin’s
anorexic effect contribute to the pathogenesis of diabetic
hyperphagia, by determining whether STZ-induced diabetes
alters the dose-response characteristics of the anorexic
response to centrally administered leptin.
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RESEARCH DESIGN AND METHODS
Animals and experimental procedures. Experiments were performed on male
Long-Evans rats that were housed individually in a temperature-controlled envi-
ronment (22o C) with a 12:12-h light:dark cycle; the rats were obtained from the
breeding colony maintained by the Department of Psychology at the University of
Washington. All rats had ad libitum access to pelleted rat food (Harlan-Teklad, Madi-
son, WI) and tap water. All procedures were performed in accordance with insti-
tutional guidelines of the Animal Care Committee at the University of Wa s h i n g t o n .
Experiment 1. One week before the experiment, rats (~250 g) were anesthetized
with an intraperitoneal injection of ketamine:xylazine (60:8 mg/kg), and an
indwelling catheter was inserted into the right jugular vein. The catheter was
extended to the level of the right atrium, and the free end of the catheter was passed
subcutaneously to the back of the neck where it was externalized and sutured in
place. Animals were treated prophylactically with gentomycin (8 mg i.m.) and were
allowed to recover to presurgical levels of body weight and daily food intake before
each experiment.
On day 0, the rats were divided into three groups of equivalent mean body
weight and daily food intake. Two groups received a subcutaneous injection 
(40 mg/kg) of freshly prepared STZ (Sigma, St. Louis, MO) in 0.5 mol citrate
buffer (pH 4.5) on each of 2 consecutive days to induce diabetes. This regimen
has been shown to produce type 1 diabetes (plasma glucose >20 mmol/l) in >95%
of treated animals without inducing renal failure or hypoglycemia (24). Subse-
q u e n t l y, under ketamine:xylazine anesthesia, one group (STZ + saline [Sal]) (n =
11) received a subcutaneous implanted osmotic minipump (Alza Scientific Prod-
ucts, Palo Alto, CA) that infused saline alone, while the other diabetic group (STZ
+ leptin [Lep]) (n = 15) received a subcutaneous implanted osmotic minipump con-
taining recombinant rat leptin (Amgen, Thousand Oaks, CA) diluted in saline with
an infusion rate of 100 µg ? k g– 1 ? d a y– 1. The third group remained nondiabetic,
receiving two consecutive daily subcutaneous injections of citrate vehicle (Ve h )
rather than STZ, and subcutaneous osmotic minipump containing saline (Con).
Plasma samples, food intake, and body weight measurements were taken every
morning for 1 week after the first STZ/Veh injection.
Blood samples (1 ml) were obtained at 0800 (normal nonfasting conditions 
1 h after “lights on”) and were placed into tubes containing EDTA (1 mg/ml).
Plasma was separated by centrifugation and red blood cells were washed and
resuspended in sterile saline and reinfused to prevent anemia. Plasma samples
were kept in an ice bath during processing and then stored at –70o C until assayed
for determination of insulin, leptin, and glucose concentrations. Plasma glucose
was determined by the glucose oxidase method (Beckman Instruments, Brea, CA).
Plasma insulin (25,26) and leptin levels (Linco, St. Louis, MO) (27) were determined
by radioimmunoassay as previously described.
Experiment 2. Two weeks before the experiment, rats (~350 g) underwent
stereotaxic cannulation of the third cerebral ventricle under ketamine:xylazine
anesthesia as previously described (28). Animals were allowed to recover to
presurgical levels of weight and food intake before the experiment was begun.
Patency of the intracerebroventricular (ICV) infusion system and verification of
cannula placement were confirmed by ICV injection of angiotension II (10 ng in
1 µl) 1 week after the surgical procedure. Animals that did not drink 5 ml of water
within 60 min after treatment were not included in the experiment.
After cannulation, rats were separated into two groups of equivalent mean body
weight and daily food intake. One group (n = 17) received a single dose of STZ
(65 mg/kg) via a tail vein under light halothane anesthesia to induce insulin-defi-
cient diabetes, while control animals (n = 13) received citrate buffer only (Ve h ) .
The two groups were subsequently maintained on their standard diet for 10 days,
and food intake and body weights were monitored daily. After diabetic hyperphagia
was established in the STZ group, rats were adapted to a schedule in which food
was removed from the cage and the animals were weighed 3 h before the end of
the light cycle. On experimental days, 45 min after the food was removed, each
animal was injected with human leptin (0, 0.35, 1.0, or 3.5 µg) (Hoffmann-
LaRoche, Nutley, NJ) in synthetic cerebrospinal fluid via the ICV cannula in a vol-
ume of 3.5 µl. Food was returned at “lights out,” and food intake was measured
over the next 4 h and again 24 h after the leptin injection. Each diabetic rat
received each dose of leptin with the order counterbalanced across subjects
using a Latin-square design, with no injections occurring on the 4 intervening days
between consecutive experimental days.
Statistics. All data are expressed as means ± SE. The level of significance was
P < 0.05. The data were analyzed for differences on the basis of group-by-group
comparisons and for changes from intragroup baseline values using one-way
analysis of variance. Statistical comparisons were made using the Statview II (Cal-
abasas, CA) computer program. Fischer’s protected least significant difference test
for multiple comparisons was used post hoc when significant F ratios were
obtained. Experiment 2 was analyzed using standard mixed-model analysis of vari-
ance (STZ versus Veh) for the between-subjects variable and dose (as the within-
subjects variable) on the raw food intake data at 4 and 24 h, followed by Tu k e y ’s
paired sample or independent t test, as appropriate.
R E S U LT S
Experiment 1. In the STZ + Sal group, plasma insulin (Fig. 1)
fell significantly from 377 ± 104 (day 0) to 202 ± 27 pmol/l by
day 3 (P < 0.05) and remained low thereafter (186 ± 
45 pmol/l, day 7), and this was associated with an increase of
plasma glucose concentrations (Fig. 1) from 8.0 ± 0.2 (day 0)
to 19.4 ± 1.7 mmol/l (P < 0.05) by day 2 and was increased
threefold over basal by the end of the experiment (24.3 ± 
1.1 mmol/l, day 7). In the STZ + Lep group, plasma insulin con-
centrations fell comparably from 317 ± 36 (day 0) to 220 ± 
28 pmol/l by day 3 (P < 0.05) and remained low for the dura-
tion of the experiment (201 ± 36 pmol/l, day 7). Hyperglycemia
was evident by day 2 (13.9 ± 1.5 mmol/l, P < 0.05) and was
increased by more than twofold over basal by day 7 (17.2 ±
1.8 mmol/l, P < 0.05) in the STZ + Lep group, but the degree
of hyperglycemia was significantly lower than that achieved
in the STZ + Sal group. In contrast, neither plasma insulin 
(378 ± 63 pmol/l, days 0–7) nor plasma glucose levels (7.7 ±
0.2 mmol/l) changed significantly over the course of the
experiment in nondiabetic controls.
Plasma leptin levels (Fig. 2) fell significantly in the STZ +
Sal group from 2.4 ± 0.5 (day 0) to 1.1 ± 0.3 ng/ml (P < 0.05)
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FIG. 1. Plasma insulin and glucose levels in control and STZ-induced
diabetic rats. After a basal period (day 0), rats received STZ injections
(40 mg/kg) on 2 successive days plus subcutaneous delivery of saline
(STZ + Sal) or recombinant rat leptin (STZ + Lep) at 100 µg ? k g– 1 ?
d a y– 1 via osmotic minipump. The Con group received Veh and subcu-
taneous saline. *P < 0.05 vs. STZ + Lep.
by day 3 and were reduced by 75% at the end of the study (0.6 ±
0.2 ng/ml, day 7). In the diabetic group receiving recombi-
nant rat leptin, plasma leptin levels increased from 2.6 ± 0.4
(day 0) to a peak of 5.9 ± 0.4 ng/ml on day 1 (P < 0.05), pre-
sumably because of exogenous leptin infusion superimposed
on the basal plasma leptin level. For the final 5 days, however,
leptin concentrations in the STZ + Lep group (2.8 ± 0.3 ng/ml)
were comparable both to pretreatment values and to levels in
the nondiabetic control group, in which the plasma leptin
concentration (3.1 ± 0.9 ng/ml, days 0–7) did not change signi-
ficantly over the course of the experiment. From days 3–7, lep-
tin levels were approximately fivefold higher (P < 0.05) in
both STZ + Lep and Con rats than in the STZ + Sal group.
Daily food intake (Fig. 2) did not differ among the three
groups on day 0 (24 ± 2 g), but declined in each group after
minipump implantation (days 1 and 2). In the STZ + Sal
group, food intake increased gradually to values 43% greater
than basal by day 7 (33 ± 3 g/day, P < 0.05). In contrast, daily
food intake in the STZ + Lep group did not exceed basal val-
ues on any day, nor did it differ significantly from control lev-
els by the end of the experiment. Body weight increased
s i g n i ficantly in the STZ + Sal group from 247 ± 10 (day 0) to
258 ± 13 g by day 7 (P < 0.05), and in the Con group (from 
246 ± 5, day 0, to 266 ± 6, day 7, P < 0.05), whereas it
decreased nonsignificantly in STZ + Lep from 254 ± 7 (day 0)
to 248 ± 9 g (day 7).
Experiment 2. Ten days after either STZ or Veh injection, the
STZ-treated rats weighed 338 ± 18 g while the controls
weighed 396 ± 12 g (P < 0.05). As expected, average daily food
intake of the STZ-treated rats was significantly elevated (39.8 ±
4.5 g) compared with controls (27.3 ± 3.7 g, P < 0.05). As
depicted in Figs. 3 and 4, ICV leptin caused dose-dependent
reductions of 4- and 24-h food intake in both groups when
compared with synthetic cerebrospinal fluid (CSF) injection.
H o w e v e r, the magnitude of the leptin effect did not differ signi-
ficantly between the two groups. The 4-h food intakes in the
group receiving the synthetic CSF injection were 6.8 ± 0.9 in
controls and 8.5 ± 1.4 g in the STZ-treated group, while the 24-
h food intakes were 28.7 ± 2.4 and 38.1 ± 4.1 g, respectively
(P < 0.05). In both groups, the lowest leptin dose (0.35 µg)
reduced 4- and 24-h food intake by 15% (P < 0.05, 24-h food
intake), while the two larger doses (1.0 and 3.5 µg) reduced
food intake by 22 and 35%, respectively (P < 0.05, both time
points). Two-way analysis of variance revealed no effect of
condition (i.e., STZ versus Veh) on the relationship between
leptin dose and the reduction in food intake, indicating that
sensitivity to the anorexic effect of ICV leptin is not altered
in rats with diabetic hyperphagia.
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FIG. 2. Plasma leptin levels and daily food intake in control and 
STZ-induced diabetic rats. After a basal period (day 0), rats received
STZ injections (40 mg/kg) on 2 successive days plus subcutaneous
delivery of saline (STZ + Sal) or recombinant rat leptin (STZ + Lep)
at 100 µg ? k g– 1 ? d a y– 1 via osmotic minipump. The Con group received
Veh and subcutaneous saline. *P < 0.05 vs. STZ + Lep.
FIG. 3. Food intake measured for 4 h after ICV administration of syn-
thetic CSF or leptin 10 days after injection of STZ or Veh. Each dose
of leptin was delivered in 3.5 µl of synthetic CSF 45 min before “lights
out,” as described in the text. *P < 0.05 vs. 0 µg dose.
D I S C U S S I O N
The pathogenesis of diabetic hyperphagia has been a focus
of investigation since it was first documented experimen-
tally more than 30 years ago (29), and many hypotheses have
been forwarded to explain the phenomenon (30). Urinary
loss of glucose, depletion of body fuel stores, and the inabil-
ity to use glucose as an energy substrate were each proposed
in early studies to explain the stimulatory effect of diabetes
on food intake. In the current study, we investigated the role
of leptin deficiency in the pathogenesis of diabetic hyper-
phagia by determining the effect on food intake of systemic
leptin infusion at a dose that maintained physiological
plasma leptin levels in rats with STZ-induced diabetes. We
found that during uncontrolled diabetes in saline-treated
rats, marked leptin deficiency developed by day 3, followed
by a gradual rise in food intake that peaked at a value 43%
above baseline. In contrast, food intake did not increase in dia-
betic rats in which leptin deficiency was prevented by exoge-
nous leptin infusion. Leptin defic i e n c y, therefore, appears to
be required for the development of hyperphagia in rats with
uncontrolled diabetes.
In o b/o b mice, genetic leptin deficiency is associated with
increased hypothalamic expression of the long form of the lep-
tin receptor (31,32) and increased sensitivity to leptin’s
anorexic effects (33). Hypoleptinemia that occurs in animals
with uncontrolled diabetes (23) could therefore increase sen-
sitivity to leptin, which might influence the effect of leptin infu-
sion on food intake. To investigate this possibility, we con-
ducted a dose-response study comparing leptin’s ability to sup-
press food intake after injection into the third ventricle of STZ-
treated rats and vehicle-treated nondiabetic controls. Despite
the characteristic hyperphagia of STZ-treated rats at baseline,
ICV leptin induced a dose-dependent suppression of food
intake that was comparable in the two groups (35% sup-
pression with largest dose) and was similar in magnitude to
results previously obtained in normal rats (13). These data
suggest that STZ-induced diabetes of short duration does
not substantially alter sensitivity to leptin-induced anorexia.
This finding is in agreement with our recent observation that
7 days of uncontrolled STZ diabetes (P.J.H., D.K.S., M.W. S . ,
unpublished observations) does not increase the hypothala-
mic expression of leptin receptor mRNA (diabetic group 100
± 3% vs. control group 100 ± 8%, NS) despite inducing a pro-
nounced decrease of plasma leptin levels. Thus, while it is pos-
sibile that longer periods of STZ diabetes would change lep-
tin sensitivity or leptin receptor expression, our results sug-
gest that neither the effect of STZ-induced diabetic
hypoleptinemia to increase food intake, nor the effect of
physiological leptin replacement to suppress diabetic hyper-
phagia, can be attributed to a change in sensitivity to leptin’s
anorexic effects.
Accompanying the prevention of diabetic hyperphagia in
the current study was a reduction in the level of hypergly-
cemia in the STZ + Lep group. One possible explanation for
this finding is that the leptin-induced reduction of food intake
in diabetic animals resulted in lower plasma glucose levels.
H o w e v e r, our data do not exclude the possibility that leptin
treatment lowered plasma glucose levels via a mechanism
unrelated to reduced food intake. Indeed, the observation that
glucose levels were lower in the leptin-treated rats during the
first 2 days of leptin infusion, despite similar levels of plasma
insulin and food intake in the two STZ diabetic groups (Fig. 2),
is consistent with an independent glucose-lowering effect of
leptin. Moreover, leptin administration to o b/o b mice lowers
glucose levels to a greater extent than can be explained by its
ability to reduce food intake, apparently via a mechanism that
does not require increased insulin secretion (14), and may
involve reduced hepatic glycogenolysis (34).
The mechanism by which leptin suppresses food intake in
diabetic animals was not addressed in the current study, but
may involve changes in hypothalamic neuropeptides previ-
ously identified as targets for the action of leptin. For exam-
ple, hypothalamic expression of mRNA encoding neuropep-
tide Y (NPY) (35), melanin-concentrating hormone (36,37),
agouti-related protein (38), and orexins A and B (39) are
each increased in conditions associated with weight loss or
leptin defic i e n c y, and each of these peptides exerts stimula-
tory effects on food intake. Conversely, melanocortins, cor-
ticotropin-releasing hormone (35), cocaine- and ampheta-
mine-regulated transcript (40), and thyrotropin-releasing hor-
mone (41) are neuropeptides that inhibit food intake, and each
is expressed at reduced levels in rat hypothalamus when lep-
tin and insulin concentrations are reduced (i.e., during fast-
ing). Based on these observations, we hypothesize that pep-
tides that stimulate food intake are overexpressed in the
hypothalamus of animals with uncontrolled diabetes, as has
been documented for NPY (28), and that this response is
attenuated by leptin replacement. Reduced expression of
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FIG. 4. Food intake measured for 24 h after ICV administration of syn-
thetic CSF or leptin 10 days after injection of STZ or Veh. Each dose
of leptin was delivered in 3.5 µl of synthetic CSF 45 min before “lights
out,” as described in the text. *P < 0.05 vs. 0 µg dose.
anorexigenic peptides (as documented for corticotropin-
releasing hormone) may also contribute to hyperphagia in dia-
betic rats. Additional studies are warranted to clarify the
hypothalamic response to uncontrolled diabetes and the
extent to which it depends on leptin defic i e n c y.
Previous investigations suggest that CNS insulin defi-
ciency plays an important role in the pathogenesis of diabetic
hyperphagia (28). This hypothesis is based on the observation
that circulating insulin enters the CNS, where it can bind to
and activate insulin receptors expressed by neurons in hypo-
thalamic areas implicated in the control of food intake, such
as the arcuate nucleus (26,28,42,43). Furthermore, ICV
insulin infusion lowers food intake in rats with STZ-diabetes,
and this effect is associated with inhibition of hypothalamic
synthesis of NPY (28). In the current studies, however, the
plasma insulin levels were significantly and comparably
reduced in both the STZ + Sal and STZ + Lep groups, sug-
gesting that insulin defic i e n c y, in and of itself, is insufficient
to cause hyperphagia in the absence of leptin defic i e n c y. This
finding does not exclude the possibility that insulin defi-
ciency contributes to diabetic hyperphagia when leptin lev-
els are low, and further study of the interaction between
insulin and leptin in the control of food intake in diabetic ani-
mals is warranted.
Many studies have demonstrated that leptin administration
lowers food intake in both normal animals and in leptin-defi-
cient o b/o b mice (13,14,44,45). Most of these studies, however,
investigated the effect of leptin administered at a pharma-
cological dose or via a nonphysiolgical route (e.g., ICV). The
current study is the first to demonstrate that the simple pre-
vention of leptin deficiency is sufficient to prevent the devel-
opment of hyperphagia in rats with uncontrolled diabetes.
This finding provides direct evidence that in genetically nor-
mal animals, a decline in leptin from the basal value
increases caloric intake, as predicted by the hypothesis that
leptin is a major signal to the brain that adipose stores are
threatened, as in starvation (35,46).
In summary, we found that STZ-induced diabetes caused a
marked decrease of the circulating plasma leptin level that
precedes the onset of diabetic hyperphagia and that restora-
tion of normal physiological plasma leptin concentrations
prevented the onset of the hyperphagic response. These fin d-
ings suggest that leptin deficiency mediates, at least in part,
the effect of uncontrolled diabetes to increase food intake.
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